Assessment of the effects of telmisalthan and olmethaltan on blood pressure, proteinuria, inflammation and oxidative stress in chronic kidney disease patients

Assessment of the effects of telmisalthan and olmethaltan on blood pressure, proteinuria, inflammation and oxidative stress in chronic kidney disease patients - Pleiotropic effect of telmisalthan and olmethaltan

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002422

Enrollment

Registered

2009-09-07

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease stage 3-5

Interventions

olmesartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Renal dysfunction: CKD stage 3-5 2) Expected survival time is more than 6 months 3) Aged 20 years over 4) Fully informed consent was obtained

Exclusion criteria

Exclusion criteria: 1) Patients who has past history of adverse effect of taking another ARB 2) Pregnancy 3) Patients who has serious liver disease and coronary heart disease or nephrotic syndrome 4) Judged inappropriate for this study by the physicians

Design outcomes

Primary

Measure	Time frame
The primary outcome is the impact of termisartan and olmesartan on blood pressure, proteinuria at four and twelve months after administration of the ARB case compared with at baseline.	—

Secondary

Measure	Time frame
The secondary outcome is the impact of termisartan and olmesartan on inflammatory and oxidative stress markers (hsCRP, IL-6, IL-10. TNF, pectsidine, PTX3, MPO, 8OHdG in urine)at four and twelve months after administration of the ARB case compared with at baseline	—

Countries

Japan

Contacts

Public ContactHirokazu Honda

Showa University School of Medicine Division of Nephrology Department of Medicine

hondah@med.showa-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026